U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H27NO3
Molecular Weight 341.4448
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPAFENONE

SMILES

CCCNCC(COc1ccccc1C(=O)CCc2ccccc2)O

InChI

InChIKey=JWHAUXFOSRPERK-UHFFFAOYSA-N
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3

HIDE SMILES / InChI

Molecular Formula C21H27NO3
Molecular Weight 341.4448
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB01182 | http://reference.medscape.com/drug/rythmol-propafenone-342307 | https://www.drugs.com/pro/propafenone.html | https://www.ncbi.nlm.nih.gov/pubmed/26588045

Propafenone (brand name Rythmol SR or Rytmonorm) is a class 1C anti-arrhythmic medication, which treats illnesses associated with rapid heartbeats such as atrial and ventricular arrhythmias. The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy. Propafenone is metabolized primarily in the liver. Because of its short half-life, it requires dosing two or three times daily to maintain steady blood levels. The long-term safety of propafenone is unknown. Because it is structurally similar to another anti-arrhythmic medicine, flecainide, similar cautions should be exercised in its use. Flecainide and propafenone, like other antiarrhythmic drugs, have been shown to increase the occurrence of arrhythmias (5.3% for propafenone, Teva physician prescribing information), primarily in patients with underlying heart disease. However, their use in structurally normal hearts is considered safe.

Originator

Sources: Journal of the American Geriatrics Society (1961), 9, 491-7.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RYTHMOL

Approved Use

Propafenone HCl Extended Release Capsules is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. Usage Considerations: •The use of propafenone ER capsules in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use propafenone ER capsules to control ventricular rate during AF. •Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The effect of propafenone on mortality has not been determined [see BOXED WARNING

Launch Date

6.2812802E11
Primary
RYTHMOL

Approved Use

Propafenone HCl Extended Release Capsules is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. Usage Considerations: •The use of propafenone ER capsules in patients with permanent AF or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not use propafenone ER capsules to control ventricular rate during AF. •Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. • The effect of propafenone on mortality has not been determined [see BOXED WARNING

Launch Date

6.2812802E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
314 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
189.94 ng/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2900 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
322.43 ng × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.61 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4.1%
PROPAFENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Other AEs: Monocyte count increased, Eosinophil count increased...
Other AEs:
Monocyte count increased (0.7%)
Eosinophil count increased (0.7%)
Platelet count decreased (0.7%)
Cardiac failure congestive (1.5%)
Coronary artery disease NOS (0.7%)
Myocardial infarction (0.7%)
Abdominal pain NOS (0.7%)
Diarrhea NOS (0.7%)
Chest pain (1.5%)
Pneumonia NOS (0.7%)
Urinary tract infection NOS (0.7%)
Prothrombin level decreased (0.7%)
Headache (0.7%)
Syncope (0.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Coronary artery disease NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Diarrhea NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Eosinophil count increased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Headache 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Monocyte count increased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Myocardial infarction 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Platelet count decreased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Pneumonia NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Prothrombin level decreased 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Syncope 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Urinary tract infection NOS 0.7%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Cardiac failure congestive 1.5%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Chest pain 1.5%
425 mg 2 times / day multiple, oral
Highest studied dose
Dose: 425 mg, 2 times / day
Route: oral
Route: multiple
Dose: 425 mg, 2 times / day
Sources:
unhealthy, adult
n = 135
Health Status: unhealthy
Condition: atrial fibrillation
Age Group: adult
Sex: M+F
Population Size: 135
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
yes
yes
yes (co-administration study)
Comment: amiodarone and tobacco (CYP1A2 inhibitor) can be expected to cause increased plasma levels of propafenone
yes
yes (co-administration study)
Comment: ketoconazole, erythromycin, saquinavir, and grapefruit juice for (CYP3A4 inhibitors) can be expected to cause increased plasma levels of propafenone; The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 sinhibition with the simultaneous administration of propafenone may significantly increase the concentration of propafenone and thereby increase the risk of proarrhythmia and other adverse event
yes
yes (pharmacogenomic study)
Comment: Multiple studies have found that genetic variants in the CYP2D6 gene influence the plasma drug levels of propafenone
Tox targets
PubMed

PubMed

TitleDatePubMed
Algorithmic complexity. A new approach of non-linear algorithms for the analysis of atrial signals from multipolar basket catheter.
2001
Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel.
2001 Apr
[Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation].
2001 Aug
[The best in 2000 on arrhythmia].
2001 Jan
[Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation].
2001 Jan
Intravenous antiarrhythmic agents.
2001 Jan
The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
2001 Jul
Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.
2001 Jul
Altered values of heart rate variability in patients with relapse of atrial fibrillation during the first week after electrical cardioversion: preliminary data.
2001 Jun
Amiodarone -- waxed and waned and waxed again.
2001 Nov
[Liver function test impairment induced by propafenone in a 73 year old woman].
2001 Nov
Late-breaking clinical trials at the American Heart Association's scientific sessions 2001.
2001 Nov 20
Transient outward current inhibition by propafenone and 5-hydroxypropafenone in cultured neonatal rat ventricular myocytes.
2001 Sep
[Atrial fibrillation. New views on an old disease].
2001 Sep-Oct
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.
2002
Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation.
2002
Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment.
2002
New use of antiarrhythmia drugs in Saskatchewan.
2002 Jan
[Efficacy and tolerance of propafenone after correction of atrial fibrillation: PEPS pharmaco-epidemiologic study].
2002 Jun
[Structure and activity relationship of propafenone and alkylesters of 2-and 4-[(3-propylamino-2-hydroxy)-propoxy]-phenylcarbamic acid].
2002 May
Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.
2002 Sep
High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes.
2003 Aug
Propafenone hepatotoxicity: report of two new cases.
2003 Feb
Class I or class III agents for atrial fibrillation: are asking the right question?
2003 Jul
Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter.
2003 Jul
[Drug therapy of atrial fibrillation].
2003 Jun 15
Propafenone versus ibutilide for post operative atrial fibrillation following cardiac surgery: neither strategy improves outcomes compared to rate control alone (the PIPAF study).
2003 Mar
In silico screening with benzofurane- and benzopyrane-type MDR-modulators.
2003 Mar
Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels.
2003 Mar
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
2003 Mar 20
Patents

Sample Use Guides

Initiate therapy with 150 mg given every 8 hours. As needed, uptitrate in 3-4 days to 225-300 mg every 8 hours
Route of Administration: Oral
Hela cells were used for activity evaluation. Proliferation percentage was determined by the SRB assay. Cells were incubated with the Propafenone at the concentrations of 0.005-0.2 g/L for 48 h, and the cell proliferation/viability was determined using the survival percentage with the cells treated only with dimethyl sulfoxide (DMSO) at 0.1% as a reference
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:02:48 UTC 2021
Edited
by admin
on Sat Jun 26 10:02:48 UTC 2021
Record UNII
68IQX3T69U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROPAFENONE
INCI   INN   MI   VANDF   WHO-DD  
INN   INCI  
Official Name English
PROPAFENONE [MI]
Common Name English
PROPAFENON HEXAL
Brand Name English
PROPAFENONE [INCI]
Common Name English
PROPAFENONE [VANDF]
Common Name English
PROPAFENONE [WHO-DD]
Common Name English
PROPAFENONE [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C93038
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
LIVERTOX 806
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
NDF-RT N0000175426
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
NCI_THESAURUS C47793
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
WHO-VATC QC01BC03
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
WHO-ATC C01BC03
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
Code System Code Type Description
EPA CompTox
54063-53-5
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
DRUG BANK
DB01182
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
IUPHAR
2561
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
DRUG CENTRAL
2291
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
ECHA (EC/EINECS)
258-955-6
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
WIKIPEDIA
PROPAFENONE
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
ChEMBL
CHEMBL631
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
FDA UNII
68IQX3T69U
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
LACTMED
Propafenone
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
PUBCHEM
4932
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
RXCUI
8754
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY RxNorm
CAS
54063-53-5
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
HSDB
7929
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
INN
3312
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
MERCK INDEX
M9178
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY Merck Index
MESH
D011405
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
NCI_THESAURUS
C61909
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
EVMPD
SUB10094MIG
Created by admin on Sat Jun 26 10:02:48 UTC 2021 , Edited by admin on Sat Jun 26 10:02:48 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
METABOLIC ENZYME -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC Population
PHARMACOKINETIC